The simultaneous targeting of ferroptosis and the tumor microenvironment through drug delivery/nanomedicine or biomaterials is feasible, but it is not included in our scope.[172, 173, 174, 175] Here, we aim to explore the feasibility of directly modulating both PD-L1 and tumor cell ferroptosis through small molecules or key proteins (e.g., transcription factors and epigenetic modulators), particularly in the context of breast cancer. This evidence concerns the gene CD274 and neoplasm.